These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 34488340)

  • 1. Targeting the Nuclear Receptor-Binding SET Domain Family of Histone Lysine Methyltransferases for Cancer Therapy: Recent Progress and Perspectives.
    Shrestha A; Kim N; Lee SJ; Jeon YH; Song JJ; An H; Cho SJ; Kadayat TM; Chin J
    J Med Chem; 2021 Oct; 64(20):14913-14929. PubMed ID: 34488340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The NSD family of protein methyltransferases in human cancer.
    Vougiouklakis T; Hamamoto R; Nakamura Y; Saloura V
    Epigenomics; 2015 Aug; 7(5):863-74. PubMed ID: 25942451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of NSD1, NSD2, and NSD3 histone methyltransferases in solid tumors.
    Topchu I; Pangeni RP; Bychkov I; Miller SA; Izumchenko E; Yu J; Golemis E; Karanicolas J; Boumber Y
    Cell Mol Life Sci; 2022 May; 79(6):285. PubMed ID: 35532818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancers and the NSD family of histone lysine methyltransferases.
    Morishita M; di Luccio E
    Biochim Biophys Acta; 2011 Dec; 1816(2):158-63. PubMed ID: 21664949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-throughput screening with nucleosome substrate identifies small-molecule inhibitors of the human histone lysine methyltransferase NSD2.
    Coussens NP; Kales SC; Henderson MJ; Lee OW; Horiuchi KY; Wang Y; Chen Q; Kuznetsova E; Wu J; Chakka S; Cheff DM; Cheng KC; Shinn P; Brimacombe KR; Shen M; Simeonov A; Lal-Nag M; Ma H; Jadhav A; Hall MD
    J Biol Chem; 2018 Aug; 293(35):13750-13765. PubMed ID: 29945974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in nuclear receptor-binding SET domain 2 (NSD2) inhibitors: An update and perspectives.
    Zhang L; Zha X
    Eur J Med Chem; 2023 Mar; 250():115232. PubMed ID: 36863225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular basis of nucleosomal H3K36 methylation by NSD methyltransferases.
    Li W; Tian W; Yuan G; Deng P; Sengupta D; Cheng Z; Cao Y; Ren J; Qin Y; Zhou Y; Jia Y; Gozani O; Patel DJ; Wang Z
    Nature; 2021 Feb; 590(7846):498-503. PubMed ID: 33361816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Covalent inhibition of NSD1 histone methyltransferase.
    Huang H; Howard CA; Zari S; Cho HJ; Shukla S; Li H; Ndoj J; González-Alonso P; Nikolaidis C; Abbott J; Rogawski DS; Potopnyk MA; Kempinska K; Miao H; Purohit T; Henderson A; Mapp A; Sulis ML; Ferrando A; Grembecka J; Cierpicki T
    Nat Chem Biol; 2020 Dec; 16(12):1403-1410. PubMed ID: 32868895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective, Small-Molecule Co-Factor Binding Site Inhibition of a Su(var)3-9, Enhancer of Zeste, Trithorax Domain Containing Lysine Methyltransferase.
    Taylor AP; Swewczyk M; Kennedy S; Trush VV; Wu H; Zeng H; Dong A; Ferreira de Freitas R; Tatlock J; Kumpf RA; Wythes M; Casimiro-Garcia A; Denny RA; Parikh MD; Li F; Barsyte-Lovejoy D; Schapira M; Vedadi M; Brown PJ; Arrowsmith CH; Owen DR
    J Med Chem; 2019 Sep; 62(17):7669-7683. PubMed ID: 31415173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The methyltransferase NSD3 has chromatin-binding motifs, PHD5-C5HCH, that are distinct from other NSD (nuclear receptor SET domain) family members in their histone H3 recognition.
    He C; Li F; Zhang J; Wu J; Shi Y
    J Biol Chem; 2013 Feb; 288(7):4692-703. PubMed ID: 23269674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5-Aminonaphthalene derivatives as selective nonnucleoside nuclear receptor binding SET domain-protein 2 (NSD2) inhibitors for the treatment of multiple myeloma.
    Wang S; Yang H; Su M; Lian F; Cong Z; Wei R; Zhou Y; Li X; Zheng X; Li C; Fu X; Han X; Shi Q; Li C; Zhang N; Geng M; Liu H; Li J; Huang X; Wang J
    Eur J Med Chem; 2021 Oct; 222():113592. PubMed ID: 34147909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent progress in the discovery of small-molecule inhibitors of the HMT EZH2 for the treatment of cancer.
    Verma SK; Knight SD
    Future Med Chem; 2013 Sep; 5(14):1661-70. PubMed ID: 24047271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. H3K36 methyltransferases as cancer drug targets: rationale and perspectives for inhibitor development.
    Rogawski DS; Grembecka J; Cierpicki T
    Future Med Chem; 2016 Sep; 8(13):1589-607. PubMed ID: 27548565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of LEM-14 inhibitor of the oncoprotein NSD2.
    Shen Y; Morishita M; Lee D; Kim S; Lee T; Mevius DEHF; Roh Y; di Luccio E
    Biochem Biophys Res Commun; 2019 Jan; 508(1):102-108. PubMed ID: 30471851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro histone lysine methylation by NSD1, NSD2/MMSET/WHSC1 and NSD3/WHSC1L.
    Morishita M; Mevius D; di Luccio E
    BMC Struct Biol; 2014 Dec; 14():25. PubMed ID: 25494638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in targeting histone H3 lysine 36 methyltransferases for cancer therapy.
    Ma S; Long G; Jiang Z; Zhang Y; Sun L; Pan Y; You Q; Guo X
    Eur J Med Chem; 2024 Aug; 274():116532. PubMed ID: 38805937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of Nuclear Receptor-Binding SET Domain Family Histone Lysine Methyltransferases in Cancer.
    Bennett RL; Swaroop A; Troche C; Licht JD
    Cold Spring Harb Perspect Med; 2017 Jun; 7(6):. PubMed ID: 28193767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone and DNA binding ability studies of the NSD subfamily of PWWP domains.
    Zhang M; Yang Y; Zhou M; Dong A; Yan X; Loppnau P; Min J; Liu Y
    Biochem Biophys Res Commun; 2021 Sep; 569():199-206. PubMed ID: 34271259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of potent small molecule inhibitors of histone lysine methyltransferase NSDs.
    Piao L; Gao Y; Xu X; Su Y; Wang YD; Zhou J; Gao Y; Fang J; Li Q; Chang S; Kong R
    Eur J Med Chem; 2024 Mar; 268():116264. PubMed ID: 38412693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.
    Fiskus W; Pranpat M; Balasis M; Herger B; Rao R; Chinnaiyan A; Atadja P; Bhalla K
    Mol Cancer Ther; 2006 Dec; 5(12):3096-104. PubMed ID: 17172412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.